Related Experiment Video
Updated: Jul 11, 2025
Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients
Published on: February 7, 2021
Evaluating distinct KRAS subtypes as potential biomarkers for immune checkpoint inhibitor efficacy in lung
Qi Wang1, Zhuoran Tang1,2, Chunyu Li3
1Department of Medical Oncology, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, China.
Background:
Despite the acknowledged predictive value of KRAS in immune checkpoint inhibitor (ICI) responses, the heterogeneous behavior of its mutations in this sphere remains largely unexplored. As of now, no studies have definitively categorized KRAS subtype variations as independent prognostic indicators for ICI responses in lung cancer patients.
Methods:
We analyzed a cohort of 103 patients, all harboring different KRAS mutation subtypes, and complemented this data with information from TCGA and GEO databases. Our research focused on delineating the relationships between KRAS mutation subtypes and factors like immunotherapy markers and immune cell composition, in addition to examining survival rates, drug sensitivity, and PD-L1 responses corresponding to distinct KRAS subtypes.
Results:
We found that the G12V and G12D subtypes demonstrated elevated expressions of immunotherapy markers, implying a potentially enhanced benefit from immunotherapy. Significant variations were identified in the distribution of naive B cells, activated CD4+ memory T cells, and regulatory T cells (Tregs) across different KRAS mutant subtypes. A notable difference was observed in the Tumor Mutation Burden (TMB) levels across the four KRAS subtypes, with the G12D subtype displaying the lowest TMB level. Furthermore, G12C subtype showcased the worst prognosis in terms of progression-free intervals (PFI), in stark contrast to the more favorable outcomes associated with the G12A subtype.
Conclusion:
Our study reveals that KRAS mutations exhibit considerable variability in predicting outcomes for LUAD patients undergoing ICI treatment. Thus, the evaluation of KRAS as a biomarker for ICIs necessitates recognizing the potential diversity inherent in KRAS mutations.
Insights
KRAS mutation subtypes significantly impact lung cancer patient responses to immune checkpoint inhibitors (ICIs). Different subtypes like G12C and G12A show varied prognoses and immunotherapy marker expression, highlighting KRAS heterogeneity.
Area of Science:
- Oncology
- Immunotherapy
- Genomics
Background:
- The predictive value of KRAS mutations for immune checkpoint inhibitor (ICI) response is known, but subtype variations remain poorly understood.
- No prior studies have established KRAS subtype differences as independent prognostic factors for ICI efficacy in lung cancer.
Purpose of the Study:
- To investigate the prognostic significance of distinct KRAS mutation subtypes in lung cancer patients treated with ICIs.
- To explore the relationship between KRAS subtypes, immunotherapy markers, immune cell profiles, and clinical outcomes.
Main Methods:
- Analysis of a 103-patient cohort with diverse KRAS mutations, supplemented by TCGA and GEO database data.
- Examination of correlations between KRAS subtypes, immunotherapy markers, immune cell composition, TMB, drug sensitivity, and PD-L1 status.
Main Results:
- KRAS G12V and G12D subtypes showed higher immunotherapy marker expression, suggesting potential for greater ICI benefit.
- Significant differences in immune cell populations (B cells, T cells, Tregs) were observed across KRAS subtypes.
- KRAS G12D exhibited the lowest Tumor Mutation Burden (TMB), while G12C demonstrated the poorest progression-free survival (PFI) compared to G12A.
Conclusions:
- KRAS mutation subtypes display considerable variability in predicting outcomes for lung adenocarcinoma (LUAD) patients receiving ICI therapy.
- Recognizing the inherent diversity of KRAS mutations is crucial for their accurate evaluation as biomarkers for ICIs.
More Related Videos
06:51Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
10:29Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
Published on: August 14, 2019